Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis

Q4 Medicine

IJU Case Reports Pub Date : 2025-03-09 DOI:10.1002/iju5.70011

Shimpei Yamashita, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin-ichi Murata, Isao Hara

{"title":"Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis","authors":"Shimpei Yamashita, Hiroki Kawabata, Yuya Iwahashi, Satoshi Muraoka, Takahito Wakamiya, Fumiyoshi Kojima, Yasuo Kohjimoto, Shin-ichi Murata, Isao Hara","doi":"10.1002/iju5.70011","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 3","pages":"223-226"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70011","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.

Case Presentation

A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.

Conclusion

Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.

Abstract Image

查看原文本刊更多论文

Pembrolizumab联合Lenvatinib治疗血液透析患者的转移性肾细胞癌

目前还没有明确的证据表明派姆单抗和lenvatinib联合治疗血液透析患者的安全性和有效性。这是第一个患者接受血液透析联合治疗转移性肾细胞癌的报告。一例60岁男性血液透析患者患有cT3bN1M0未分类肾细胞癌。他接受了派姆单抗加lenvatinib的联合治疗。虽然由于3级血小板减少，lenvatinib的剂量减半至10 mg/天，但6个月后，原发病变和淋巴结转移的体积显着减少。结论我们的病例报告提示了派姆单抗联合lenvatinib治疗血液透析转移性肾癌患者的可行性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊